AAVnerGene Inc., an innovative biotech company based in Rockville, MD, known for its cutting-edge AAV tissue-targeted delivery and manufacturing technologies, has partnered with Klotho Neurosciences Inc. to unlock the full potential of gene therapy. This collaboration aims to redefine the future of healthcare by combining AAVnerGene’s state-of-the-art AAV production platform and Klotho’s precision therapeutic candidates.
Klotho’s portfolio focuses on cell and gene therapies, with programs utilizing RNA and DNA-based diagnostics and therapeutic assays. AAVnerGene, on the other hand, brings its groundbreaking AAVone system a single-plasmid, high-yield AAV production technology that reduces manufacturing costs—along with ATHENA, which offers precise tissue targeting for gene therapies.
A Partnership Built for the Future of Healthcare
Dr. Joseph Sinkule, CEO of Klotho Neurosciences, highlighted the tremendous potential of this partnership, saying, “We’ve been looking for a solution to unlock efficiencies in manufacturing next-generation gene therapies. AAVnerGene’s platforms, with their low-cost, high-efficiency approach, will accelerate our gene therapy candidates, including KLTO-101 for Alzheimer’s and Parkinson’s diseases, KLTO-303 for aging-related conditions, and KLTO-202 for ALS and other motor neuron diseases. These therapies have the potential to offer a healthier and longer lifespan to patients.”
Dr. Sinkule also expressed confidence in AAVnerGene’s capabilities: “With AAVnerGene’s method, we are confident in producing therapies with minimal impurities, low toxicity, and high efficacy, thanks to its excellent tissue-specific delivery.”
Solving Challenges in Gene Therapy with Innovative Platforms
Dr. Daozhan Yu, Founder and CEO of AAVnerGene, shared his excitement about the collaboration: “AAV gene therapy is a game-changing, one-time treatment, but it faces challenges such as high dosages, toxicity, and cost. We recognized these challenges six years ago and set out to solve them. Our proprietary platforms are designed to address these issues, and Klotho’s data on neuron longevity and safety is truly remarkable. Together, we aim to create affordable and effective treatments for both common and rare diseases.”
Looking Ahead: A Healthier Future Through Innovation
The partnership between AAVnerGene and Klotho Neurosciences is poised to make significant strides in the world of gene therapy, focusing on addressing the needs of patients suffering from neuromuscular and neurologic diseases. By combining the best of both companies’ technologies, they are set to provide life-changing treatments to those in need, at an affordable cost, and with the potential for long-lasting impact.
Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com
